Literature DB >> 9285564

Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor.

M S Sheikh1, F Carrier, A C Johnson, S E Ogdon, A J Fornace.   

Abstract

Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells. A p53 binding site residing at position -265/-239 in the EGF-R proximal promoter has also been identified. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53Ala143 enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identified a wild-type p53 responsive 62 bp region residing at position -167/-105. The -167/-105 segment was responsive only to wild-type p53 but not to mutant p53Ala143 or p53His273. The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identified an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position -167/-105 and is proximal to recently identified p53 binding element located at position -265/-239 in the EGF-R promotor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285564     DOI: 10.1038/sj.onc.1201264

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

Review 2.  Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.

Authors:  Mark E Sharafinski; Robert L Ferris; Soldano Ferrone; Jennifer R Grandis
Journal:  Head Neck       Date:  2010-10       Impact factor: 3.147

3.  PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers.

Authors:  P Klanrit; P Taebunpakul; M B Flinterman; E W Odell; M A Riaz; G Melino; P Salomoni; J S Mymryk; J Gäken; F Farzaneh; M Tavassoli
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

4.  Notch-1 regulates transcription of the epidermal growth factor receptor through p53.

Authors:  Benjamin W Purow; Tilak K Sundaresan; Michael J Burdick; Benjamin A Kefas; Laurey D Comeau; Michael P Hawkinson; Qin Su; Yuri Kotliarov; Jeongwu Lee; Wei Zhang; Howard A Fine
Journal:  Carcinogenesis       Date:  2008-03-20       Impact factor: 4.944

5.  Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53 K317R knock-in mouse thymocytes.

Authors:  Lisa M Miller Jenkins; Sharlyn J Mazur; Matteo Rossi; Olga Gaidarenko; Yang Xu; Ettore Appella
Journal:  Mol Cell Proteomics       Date:  2008-01-04       Impact factor: 5.911

6.  Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes.

Authors:  A Bheda; K E Creek; L Pirisi
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

7.  Multiple testing for gene sets from microarray experiments.

Authors:  Insuk Sohn; Kouros Owzar; Johan Lim; Stephen L George; Stephanie Mackey Cushman; Sin-Ho Jung
Journal:  BMC Bioinformatics       Date:  2011-05-26       Impact factor: 3.169

8.  EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy.

Authors:  Nai-Wen Su; Yi-Shing Leu; Jehn-Chuan Lee; Chung-Ji Liu; Chieh-Yuan Cheng; Jiun-Sheng Lin; Yu-Jen Chen; Chi-Kuan Chen; I-Chih Fang; Ruey-Kuen Hsieh; Yi-Fang Chang
Journal:  Onco Targets Ther       Date:  2014-11-28       Impact factor: 4.147

9.  Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.

Authors:  V H de Almeida; A C de Melo; D D Meira; A C Pires; A Nogueira-Rodrigues; H K Pimenta-Inada; F G Alves; G Moralez; L S Thiago; C G Ferreira; C Sternberg
Journal:  Braz J Med Biol Res       Date:  2017-11-13       Impact factor: 2.590

10.  p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.

Authors:  Shin-Hyung Park; Myeong-A Seong; Ho-Young Lee
Journal:  Oncotarget       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.